FDA Approves Oral Form of Edaravone for the treatment of ALS (Lou Gehrig's disease)

"FDA has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). Radicava ORS is an orally administered version of Radicava, which was originally approved in 2017 as an intravenous (IV) infusion to treat ALS, commonly referred to as Lou Gehrig’s disease."

FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS) | FDA